Literature DB >> 21550554

History of small-cell lung cancer.

Shadi Haddadin1, Michael C Perry.   

Abstract

The history of small-cell lung cancer (SCLC) is one of the more fascinating stories of medicine, a story of hope and disappointment that characterizes it as 1 of the most elusive cancers. Its history can be divided into 3 intervals. The first interval encompassed the 30 years after the initial reports from Bernard in 1926 during which SCLC was characterized. The second interval, from the 1960s-1980s, introduced advances in staging and treatment of SCLC and the advent of chemotherapy and radiation therapy (RT) as the primary forms of therapy. The final interval covers the past 25 years, which is considered a dormant period, although there are some shimmers of hope from the emergence of several new active drugs that are currently undergoing clinical trials.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21550554     DOI: 10.1016/j.cllc.2011.03.002

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  16 in total

1.  The evolving role of the pathologist in the management of lung cancer.

Authors:  Adi F Gazdar
Journal:  Lung Cancer Manag       Date:  2012

Review 2.  Chemotherapy advances in small-cell lung cancer.

Authors:  Bryan A Chan; Jermaine I G Coward
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

3.  Long non-coding RNA TUG1: a novel therapeutic target in small cell lung cancer.

Authors:  Chunlin Ou; Guiyuan Li
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

4.  Prognostic indicators of survival in patients with small-cell lung cancer at a tertiary care center in Lebanon.

Authors:  Arafat Tfayli; Hanine Atwi; Amal Naji; Majd Al Assaad; Sahar Assi; Maya Hazimeh
Journal:  SAGE Open Med       Date:  2021-08-13

Review 5.  Small-cell lung cancer: what we know, what we need to know and the path forward.

Authors:  Adi F Gazdar; Paul A Bunn; John D Minna
Journal:  Nat Rev Cancer       Date:  2017-10-27       Impact factor: 60.716

6.  Combined small-cell lung carcinoma: An institutional experience.

Authors:  Audrey S Wallace; Monika Arya; Shellaine R Frazier; Steven Westgate; Zhenyu Wang; Donald Doll
Journal:  Thorac Cancer       Date:  2014-01-02       Impact factor: 3.500

7.  New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases.

Authors:  Charles Dayen; Didier Debieuvre; Olivier Molinier; Olivier Raffy; Fabrice Paganin; Jérôme Virally; Sébastien Larive; Béatrice Desurmont-Salasc; Marielle Perrichon; Francis Martin; Michel Grivaux
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

8.  Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes.

Authors:  Alexander Krohn; Theresa Ahrens; Arzu Yalcin; Till Plönes; Julius Wehrle; Sanaz Taromi; Stefan Wollner; Marie Follo; Thomas Brabletz; Sendurai A Mani; Rainer Claus; Björn Hackanson; Meike Burger
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

9.  Evaluation of Rumex hastatus D. Don for cytotoxic potential against HeLa and NIH/3T3 cell lines: chemical characterization of chloroform fraction and identification of bioactive compounds.

Authors:  Sajjad Ahmad; Farhat Ullah; Anwar Zeb; Muhammad Ayaz; Farman Ullah; Abdul Sadiq
Journal:  BMC Complement Altern Med       Date:  2016-08-24       Impact factor: 3.659

10.  Staurosporine and extracellular matrix proteins mediate the conversion of small cell lung carcinoma cells into a neuron-like phenotype.

Authors:  Tamara Murmann; Carmen Carrillo-García; Nadine Veit; Cornelius Courts; Alexander Glassmann; Viktor Janzen; Burkhard Madea; Markus Reinartz; Anne Harzen; Michael Nowak; Sven Perner; Jochen Winter; Rainer Probstmeier
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.